292 related articles for article (PubMed ID: 25764118)
1. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Urol Rep; 2015 Apr; 16(4):24. PubMed ID: 25764118
[TBL] [Abstract][Full Text] [Related]
2. Defining 'progression' and triggers for curative intervention during active surveillance.
Klotz L
Curr Opin Urol; 2015 May; 25(3):258-66. PubMed ID: 25714238
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance for low-risk prostate cancer.
Klotz L
Curr Opin Urol; 2017 May; 27(3):225-230. PubMed ID: 28267056
[TBL] [Abstract][Full Text] [Related]
4. Active surveillance and focal therapy for low-intermediate risk prostate cancer.
Klotz L
Transl Androl Urol; 2015 Jun; 4(3):342-54. PubMed ID: 26816834
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Active Surveillance.
Carter HB
Eur Urol; 2016 Dec; 70(6):909-911. PubMed ID: 27460354
[TBL] [Abstract][Full Text] [Related]
6. Preventing clinical progression and need for treatment in patients on active surveillance for prostate cancer.
Goldberg H; Klaassen Z; Chandrasekar T; Fleshner N
Curr Opin Urol; 2018 Jan; 28(1):46-54. PubMed ID: 29028765
[TBL] [Abstract][Full Text] [Related]
7. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.
Wang JH; Downs TM; Jason Abel E; Richards KA; Jarrard DF
Curr Urol Rep; 2017 Jul; 18(7):48. PubMed ID: 28589399
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
9. Active surveillance in intermediate-risk prostate cancer.
Klotz L
BJU Int; 2020 Mar; 125(3):346-354. PubMed ID: 31647166
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based approach to active surveillance of prostate cancer.
Witherspoon L; Breau RH; Lavallée LT
World J Urol; 2020 Mar; 38(3):555-562. PubMed ID: 30726506
[TBL] [Abstract][Full Text] [Related]
11. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
12. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
13. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
14. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
15. The role of MRI in active surveillance for men with localized prostate cancer.
Recabal P; Ehdaie B
Curr Opin Urol; 2015 Nov; 25(6):504-9. PubMed ID: 26372037
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance for prostate cancer: current evidence and contemporary state of practice.
Tosoian JJ; Carter HB; Lepor A; Loeb S
Nat Rev Urol; 2016 Apr; 13(4):205-15. PubMed ID: 26954332
[TBL] [Abstract][Full Text] [Related]
17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
19. Management of low risk prostate cancer: active surveillance and focal therapy.
Klotz L; Emberton M
Curr Opin Urol; 2014 May; 24(3):270-9. PubMed ID: 24710055
[TBL] [Abstract][Full Text] [Related]
20. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
